Latest filing published 02 Apr 2026 for Terns Pharmaceuticals, Inc., €43k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Emil Kuriakose across 2 companies, led by Terns Pharmaceuticals, Inc. and Calithera Biosciences, Inc. We count 13 filings; the first trade dates from 5 November 2021 and the latest from 1 April 2026.
Sales make up the whole of the open-market record (7 sales, €117k). Other entries cover 6 share grants. Since January 2026: no purchases and 3 sales on the market.
The newest entry dates from 2 April 2026: an open-market sale of €43k, in Terns Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
11 of 11 declarations